Compare RAND & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RAND | SER |
|---|---|---|
| Founded | 1969 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.2M | 42.0M |
| IPO Year | N/A | 2018 |
| Metric | RAND | SER |
|---|---|---|
| Price | $16.31 | $2.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 4.7K | ★ 15.1K |
| Earning Date | 11-07-2025 | 11-13-2025 |
| Dividend Yield | ★ 7.27% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,327,287.00 | $116,000.00 |
| Revenue This Year | N/A | $134.46 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.25 | $3.12 |
| 52 Week High | $31.89 | $7.92 |
| Indicator | RAND | SER |
|---|---|---|
| Relative Strength Index (RSI) | 67.10 | 26.45 |
| Support Level | $15.65 | $3.15 |
| Resistance Level | $17.49 | $4.26 |
| Average True Range (ATR) | 0.60 | 0.23 |
| MACD | 0.25 | -0.03 |
| Stochastic Oscillator | 72.17 | 1.47 |
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.